文献速递淋巴瘤

达里纳帕生治疗复发或难治性外周T细胞淋巴瘤:亚洲2期研究结果

Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study.
PubMed 文献 · Blood Adv · 2023-01-01

这项2期、非随机、单臂、开放标签研究在65例亚洲复发或难治性外周T细胞淋巴瘤患者中评估了静脉达里纳帕生(300 mg/m2,1小时输注,每日1次,连续5天,每21天为一周期)的疗效、安全性和多剂量药代动力学。中心评估的总体缓解率为19.3%(90%CI 11.2-29.9),显著高于预设的10%阈值(P=0.024)。治疗中出现的不良事件发生率为98.5%,达里纳帕生有效且耐受性良好,不良事件临床可接受,可通过对症治疗和减量管理。

要点

  • 中心评估总体缓解率为19.3%(90%CI 11.2-29.9),显著高于预设10%阈值(P=0.024)。
  • 外周T细胞淋巴瘤-非特指型患者缓解率为16.2%,血管免疫母细胞性T细胞淋巴瘤患者为29.4%。
  • 3级及以上治疗中出现的不良事件发生率≥5%的包括贫血(15.4%)、血小板减少(13.8%)、中性粒细胞减少(12.3%)等。

核心结论

  • 达里纳帕生有效且耐受性良好,治疗中出现的不良事件临床可接受,可通过对症治疗和减量管理。

研究设计与样本

  • 2期、非随机、单臂、开放标签研究,纳入65例亚洲复发或难治性外周T细胞淋巴瘤患者。
  • 给药方案为静脉达里纳帕生300 mg/m2,1小时输注,每日1次,连续5天,每21天为一周期。
  • 主要终点为总体缓解率,同时评估多剂量药代动力学。

主要发现

  • 中心评估的总体缓解率为19.3%(90%CI 11.2-29.9),显著高于预设的10%阈值(P=0.024)。
  • 外周T细胞淋巴瘤-非特指型患者缓解率为16.2%,血管免疫母细胞性T细胞淋巴瘤患者为29.4%。
  • 62.3%的患者肿瘤缩小。
  • 治疗中出现的不良事件发生率为98.5%。
  • 3级及以上治疗中出现的不良事件发生率≥5%的包括贫血(15.4%)、血小板减少(13.8%)、中性粒细胞减少(12.3%)、白细胞减少(9.2%)、淋巴细胞减少(9.2%)和高血压(6.2%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Darinaparsin is a novel organic arsenical compound of dimethylated arsenic conjugated to glutathione, with antitumor activity and a mechanism of action markedly different from other available agents. This phase 2, nonrandomized, single-arm, open-label study evaluated the efficacy and safety of intravenous darinaparsin (300 mg/m2 over 1 hour, once daily for 5 consecutive days, per 21-day cycle) and its pharmacokinetics at multiple doses in 65 Asian patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The primary end point was the overall response rate (ORR). The ORR based on central assessment was 19.3% (90% confidence interval, 11.2-29.9), which was significantly higher than the predefined threshold of 10% (P = .024). The ORR was 16.2% in patients with PTCL-not otherwise specified and 29.4% in patients with angioimmunoblastic T-cell lymphoma. Tumor size decreased in 62.3% of patients. Treatment-emergent adverse events (TEAEs) were observed in 98.5% of patients. Grade ≥3 TEAEs with an incidence rate of ≥5% included anemia (15.4%), thrombocytopenia (13.8%), neutropenia (12.3%), leukopenia (9.2%), lymphopenia (9.2%), and hypertension (6.2%). Darinaparsin is effective and well tolerated, with TEAEs that were clinically acceptable and manageable with symptomatic treatment and dose reductions. This trial was registered at www.clinicaltrials.gov as #NCT02653976.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kim WS, Fukuhara N, Yoon DH, et al. Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study. Blood Adv. 2023. PMID: 36661315. doi:10.1182/bloodadvances.2022008615

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。